Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Karie Danielle Keera Runcie, MD
Advertisement
Articles by Karie Danielle Keera Runcie, MD
Advertisement
Latest Updated Articles
Early Recurrence Post-Pembrolizumab Inspires Zanzalitinib Trial in ccRCCPublished: July 31st 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
3
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
4
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
5
